We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.10 | -7.02% | 1.325 | 1.30 | 1.35 | 1.425 | 1.325 | 1.43 | 2,958,047 | 14:52:56 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 4.47M | -40.44M | -0.0522 | -0.25 | 10.24M |
Date | Subject | Author | Discuss |
---|---|---|---|
22/4/2020 07:42 | Very intriguing. I too cannot see it as a positive but we will see; the proof is in the eating of the licensing deal (bit of a mixed metaphor). One silver lining is that the costs will be lower because presumably Carl will be off the payroll.... | nobbygnome | |
22/4/2020 07:42 | peachie, now now....hehe | qs99 | |
22/4/2020 07:41 | “After discussions with the board and major shareholders” does suggest he was encouraged out maybe ? Otherwise why involve major shareholders. He would just be telling them he is leaving ? No major share holders have dumped on back of what they knew was coming btw | peachie 74 | |
22/4/2020 07:38 | Non taken best. As holders let’s hope the deal in the US is a real good one eh ! Perhaps he was nobbling the cleaner ! | peachie 74 | |
22/4/2020 07:36 | I didn’t comment that the Products success was down to one Man although he founded the company I was just slightly frustrated that your Posts put a slightly positive spin on the News nothing else and I will leave it at that No offensive intended | best1467 | |
22/4/2020 07:32 | well the messaging will go on behind the scenes and talks of being in conjunction with the shareholders no, so maybe city have forced him out? | qs99 | |
22/4/2020 07:30 | I did not say it’s not a negative. Seeing Carl’s presentations and knowing what he’s done for the company, etc would make you want him to stay But the products success is not wholly down to one man. I don’t have my head in the sand , esp the spring ! | peachie 74 | |
22/4/2020 07:20 | This help US deal happen sooner rather than later too. He wouldn’t carry on if it was ages away. | peachie 74 | |
22/4/2020 07:19 | The world and people move on for a whole host of personal or professional reasons. No reflection on the product. US deal still happening. If it was dead in the water he would not carry on helping it over the line, that’s one good thing. And if it was even a poor deal he wouldn’t hang on as to tarnish his reputation. Who knows his reasons , wife might be ill, etc. No real point speculating. Main thing is him carrying on pushing US deal through and confidence in Feraccru. If it was for anything negative regards company or product it would have to be declared. On wards and upwards. We still have a proven derisked product FDA broad label approved to compete with IV administration for the worlds biggest deficiency. GLA | peachie 74 | |
22/4/2020 07:16 | Because they need a big biz guy to close the deal with US. Watts has the right cv Tim Watts has been appointed as Chief Executive Officer from his role as Chief Financial Officer (CFO), which he has occupied since August 2018 and will be appointed to the Board in due course. Tim has extensive biotech and Pharmaceutical experience, having previously been CFO of Oxford BioMedica PLC and Archimedes Pharma Ltd, preceded by 22 years at AstraZeneca. His knowledge of the Company and his strong biopharmaceutical background will be critical to further advancing the business." Sounds like a deal is close, they mention it twice Recognising the value to Shield and its shareholders of successfully completing the ongoing US partnering activities for Feraccru(R)/Accrufer and in the USA the product will be marketed as Accrufer (R) with Shield currently in the process of selecting a commercialisation partner. | czar | |
22/4/2020 07:13 | Not sure what to make of that Could be down to H2H Fiasco or lack of USA deal But from what I have seen of Carl he can certainly Present and Comes over as very confident the CFO is certainly no match in that department from the number of presentations I’ve seen. Things have undoubtedly gone on behind the scenes hopefully the consequences or not too detrimental | best1467 | |
22/4/2020 07:10 | Strange but at least staying til US deal done | deeppockets | |
22/4/2020 07:08 | Not the RNS I was expecting. Bit confused, why would he leave now? | daveboy1 | |
21/4/2020 18:22 | Few profits being taken. Some people will have doubled their money. Good to see some interest and volume. News got to be on its way | peachie 74 | |
21/4/2020 14:33 | I'll take 5% a day at this rate! | qs99 | |
21/4/2020 14:07 | There is definitely going on, shareprice talk and this shouting something soon. Very strong in a sell off market. 270p my target. | montyhedge | |
21/4/2020 13:26 | Very strong in this market. | montyhedge | |
21/4/2020 09:10 | Bor is a curious character who always seems to be subtly deramping. Not sure what his game is but best ignored. | nobbygnome | |
21/4/2020 09:07 | Looks the the rogue buyer / dumper is back today !!! | peachie 74 | |
21/4/2020 09:00 | Very strong in this market. | montyhedge | |
21/4/2020 08:38 | Hmm, that's one conspiracy theory I'm not buying into. How about they are just massively undervalued with a triple prong of news and positive action to update on.. The market, as ever, reacts in it's own time and fashion, and if it was straightforward we'd all be millionaires. | daveboy1 | |
21/4/2020 08:38 | Borromoni ,,, are you saying shares only rise on news also !? | peachie 74 | |
21/4/2020 08:36 | More persistent buying....GLA, will we get North of £1.50 at this rate this week? | qs99 | |
21/4/2020 08:36 | So why do the sells not show. You are suggesting the shares are “ back handed” to the MMs for them to sell | peachie 74 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions